

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/089,214	03/25/2002	Wilhelmus Hubertus Joseph Boesten	246152016400	2470	
75	90 09/21/2004		EXAMINER		
Morrison & Foerster			LUKTON, DAVID		
Suite 500 3811 Valley Ce	tre Drive	ART UNIT	PAPER NUMBER		
San Diego, CA 92130-2332			1653		
			DATE MAILED: 09/21/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applicati	on No.	Applicant(s)			
			14	BOESTEN ET AL.			
Office Action Summary		Examine	r	Art Unit			
		David Lu	kton	1653			
	The MAILING DATE of this commun	ication appears on th	e cover sheet with the c	orrespondence address			
Period fo	• •			0) = 0.11			
THE   - External after - If the - If NC - Failu Any	ORTENED STATUTORY PERIOD F MAILING DATE OF THIS COMMUNI nsions of time may be available under the provisions SIX (6) MONTHS from the mailing date of this comm period for reply specified above is less than thirty (3 period for reply is specified above, the maximum st re to reply within the set or extended period for reply reply received by the Office later than three months and patent term adjustment. See 37 CFR 1.704(b).	ICATION. of 37 CFR 1.136(a). In no extraction. 0) days, a reply within the statutory period will apply and will, by statute, cause the apply.	vent, however, may a reply be tim tutory minimum of thirty (30) day vill expire SIX (6) MONTHS from plication to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication D (35 U.S.C. § 133).	n.		
Status							
1)	Responsive to communication(s) file	ed on <u>08 March 2004</u>					
	• • • • • • • • • • • • • • • • • • • •	2b)⊠ This action is r					
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims						
5) 6) 7)	Claim(s) 1-13 is/are pending in the a 4a) Of the above claim(s) is/a Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) 1-13 are subject to restricti	re withdrawn from co					
Applicat	ion Papers						
∙9)□	The specification is objected to by th	e Examiner.					
10)	The drawing(s) filed on is/are:	a) accepted or b	) ☐ objected to by the I	Examiner.			
	Applicant may not request that any obje		_				
11)[	Replacement drawing sheet(s) including The oath or declaration is objected to				d).		
Priority (	ınder 35 U.S.C. § 119				,		
a).	Acknowledgment is made of a claim  All b) Some * c) None of:  1. Certified copies of the priority  2. Certified copies of the priority  3. Copies of the certified copies application from the Internation	documents have been documents have been of the priority documental Bureau (PCT Ru	en received. en received in Applicati ents have been receive le 17.2(a)).	on No ed in this National Stage			
Attachmen	t(s) ee of References Cited (PTO-892)		4) Intension Summers	(PTO 412)			
	e of References Cited (P10-892) e of Draftsperson's Patent Drawing Review (F	PTO-948)	4) Interview Summary Paper No(s)/Mail Da				
3) Infor	mation Disclosure Statement(s) (PTO-1449 or r No(s)/Mail Date		5) Notice of Informal P 6) Other:	atent Application (PTO-152)			

Serial No. 10/089,214 Art Unit 1653

Restriction to one of the following inventions is required under 35 U.S.C. §121:

- I. Claims 1-7, drawn to a method of making or using a peptide
- II. Claims 8-13, drawn to a dipeptide.

The claimed inventions are distinct.

Claims 1-3 (on the one hand) and claim 8 (on the other hand) related as process of making and product made. The inventions are distinct if either or both of the following can be shown:

(1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP 806.05(f)).

Claim 8 (on the one hand) and claims 4-7 (on the other hand) can be regarded as related as product and process of use; this is because claims 4-7 are not drawn to a method of making the compound of claim 8, but rather using the compound of 8 as a synthetic intermediate. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP 806.05(h)). However, in the event that Group II is elected, and claims found allowable, the corresponding method-of-

Serial No. 10/089,214 Art Unit 1653

use and method-of-making claims will be rejoined therewith.

Applicant is advised that for the response to this requirement to be complete, an election of the invention to be examined must be indicated, even if the requirement is traversed (37 C.F.R. 1.143).

Applicant is reminded that upon cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).

In the event that Group I is chosen for initial examination, applicants are required under 35 U.S.C. §121 to elect two species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. The first "specie" is a specific compound that is the target of the synthesis. (Note that in the case of claims 5-7, the final product is not a dipeptide of formula 1). Also required is election of a specific "activating agent" (as recited in claim 1).

Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a generic claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are witten in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP 809.02(a).

Should applicant traverse on the ground that the species are not patentable distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. §103 of the other invention.

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to

final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 0.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Lukton whose telephone number is 571-272-0952. The examiner can normally be reached Monday-Friday from 9:30 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber, can be reached at 571-272-0925. The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

PATENT EXAMPLER
GROUP 1800